Eliem Therapeutics Inc (ELYM)
10.16
+1.76
(+21.04%)
USD |
NASDAQ |
May 03, 16:00
10.14
-0.02
(-0.15%)
After-Hours: 20:00
Eliem Therapeutics Cash from Operations (TTM): -20.60M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -20.60M |
| September 30, 2023 | -28.10M |
| June 30, 2023 | -35.77M |
| March 31, 2023 | -41.77M |
| December 31, 2022 | -37.37M |
| September 30, 2022 | -36.80M |
| June 30, 2022 | -45.60M |
| Date | Value |
|---|---|
| March 31, 2022 | -40.11M |
| December 31, 2021 | -36.07M |
| September 30, 2021 | -33.81M |
| June 30, 2021 | -23.23M |
| March 31, 2021 | -18.51M |
| December 31, 2020 | -14.10M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-45.60M
Minimum
Jun 2022
-14.10M
Maximum
Dec 2020
-31.68M
Average
-35.77M
Median
Jun 2023
Cash from Operations (TTM) Benchmarks
| Alpine Immune Sciences Inc | -79.01M |
| Candel Therapeutics Inc | -34.24M |
| Cyclacel Pharmaceuticals Inc | -16.11M |
| Lipocine Inc | -11.87M |
| GlycoMimetics Inc | -34.88M |